Manuscripts
Showing 1533 manuscripts.
Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women
Citation
Nahida Chakhtoura, Patrick Jean-Philippe, Scott Evans, Amita Gupta, Grace Montepiedra, Soyeon Kim, Adriana Weinberg, Gerhard Theron, Timothy R Sterling, Sylvia M LaCourse, Sarah Bradford. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clinical Infectious Diseases. 2021. 73PMID: 33146706Year
2021
Journal
Clinical Infectious Diseases
Study
P1078
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
Citation
Renee Browning, Mercy Mutambanengwe, Nahida Chakhtoura, Vongai Chanaiwa, Grace Montepiedra, Mandisa Nyati, Lisa Aaron, Tsungai Mhembere, Katie McCarthy, Fuanglada Tongprasert, Sarah Bradford, Anneke Hesseling, Tichaona Vhembo, Katherine Shin, Lynda Stranix-Chibanda, Bonnie Zimmer, Gaerolwe R Masheto, Diane Costello, Kamunkhwala Gausi, Avy Violari, Patrick Jean-Philippe, Lubbe Wiesner, Blandina T Mmbaga, Timothy R Sterling, Jennifer Norman, Linda Aurpibul, Gerhard Theron, Carole L Wallis, Ramesh Bhosale, Adriana Weinberg, Carolyne Onyango-Makumbi, Neetal Nevrekhar, Amita Gupta, Tsungai Chipato, Vanessa Rouzier, Paolo Denti, David W Haas, Enid Kabugho, IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical Pharmacology & Therapeutics. 2021. 109: 1034-1044. PMID: 32909316Year
2021
Journal
Clinical Pharmacology & Therapeutics
Study
P1078
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age
Citation
Hans M Spiegel, Catherine M Gordon, Rohan Hazra, George K K Siberry, Jane C Lindsey, Denise L Jacobson. Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age. Clinical Infectious Diseases. 2021. 72: 1059-1063. PMID: 32584996Year
2021
Journal
Clinical Infectious Diseases
Study
P1076
Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding
Citation
Konstantia Nadia Angelidou, Allen Matubu, Mary Glenn Fowler, Friday Saidi, Judith S Currier, Patience Atuhaire, IMPAACT 1077BF/FF PROMISE Study Team, Dingase Dula, Dhayendre Moodley, Gift Chareka, Neetal Nevrekar, Tichaona Vhembo, Lee Fairlie, Gerhard Theron, Pendo Mlay, Kathleen George, Michael Basar, Sean S Brummel, Nahida Chakhtoura, Taha E Taha, Renee Browning. Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding. Journal of Acquired Immune Deficiency Syndromes. 2021. 86: 450-454. PMID: 33273210Year
2021
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077FF, 1077BF
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV
Citation
Rowena Espina, Mauricio Pinilla, Edmund V Capparelli, Alice M Stek, Mark Mirochnick, Emily Barr, Brookie M Best, Adriana Weinberg, IMPAACT P1026s Protocol Team, Jaime G Deville, Irma L Febo, Mikhaela Cielo, Kathleen George, Kayla Denson, Kittipong Rungruengthanakit, David E Shapiro, Elizabeth Smith, Nahida Chakhtoura, James F Rooney, Kristina M Brooks, Richard Haubrich, Jeremiah D Momper. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. AIDS. 2021. 35: 407-417. PMID: 33252495Year
2021
Journal
AIDS
Study
P1026S
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study
Citation
Camlin Tierney, Bryan Nelson, Anne Coletti, Yvonne Bryson, Mark Cotton, Stephen Spector, Mark Mirochnick, Rebecca LeBlanc, Christina Reding, Bonnie Zimmer, Deborah Persaud, Mutsa Bwakura-Dangarembizi, Kimesh Naidoo, Rohan Hazra, Theodore Ruel, Patrick Jean-Philippe, Edmund Capparelli, Ellen Chadwick. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2021. 8: e149-e157. PMID: 33242457Year
2021
Journal
Lancet HIV
Study
P1115
Pharmacokinetics and safety of maraviroc in neonates
Citation
Ellen Chadwick, Pearl Samson, Kevin Butler, IMPAACT 2007 Study Team, John Moye, Elizabeth Smith, Sarah Bradford, Christina Reding, Sisinyana Mathiba, Sherika Hanley, Mariam Aziz, James Homans, Edward Acosta, William Murtaugh, Manoli Vourvahis, Lynn Mcfadyen, Julia Rosebush, Katy Hayward, Brookie Best, Mark Mirochnick. Pharmacokinetics and safety of maraviroc in neonates. AIDS. 2021. 35: 419-427. PMID: 33252481Year
2021
Journal
AIDS
Study
IMPAACT 2007
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial
Citation
Dorothy Sebikari , Mary Glenn Fowler, Jim Aizire, George K Siberry , Sufia Dadabhai, PROMISE P1084s study team, Admire Zanga, Cynthia Mukwasi-Kahari, Tichaona Vhembo, Avy Violari, Gerard Theron, Dhayandre Moodley , Kathleen George, Bo Fan, Markus J Sommer, Renee Browning, Lynne M Mofenson, Lynda Stranix-Chibanda, John Shepherd, Camlin Tierney, Bryan Nelson. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS One. 2021. 16: e0246272. PMID: 33544759Year
2021
Journal
PLoS One
Study
P1084s
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Citation
Benjamin Johnston, Jeremiah D. Momper, Chelsea Krotje, Roger L. Shapiro, Lee Fairlie, Navdeep Thoofer, Risa Hoffman, James F. Rooney, Paul E. Sax, Lisa Frenkel, Sikhulile Moyo, K. Rivet Amico, Nahida Chakhtoura, Lameck Chinula, Jeffrey S. A. Stringer, Judith Currier, Gaerolwe Masheto, IMPAACT 2010/VESTED study team and investigators, Shahin Lockman, Violet Korutaro, Sean Brummel, Haseena Cassim, Lauren Ziemba, Blandina Mmbaga, Lynda Stranix-Chibanda, Esau Joao, Katie McCarthy, Sherika Hanley, Anne Coletti, Lynette Purdue, Patrick Jean-Philippe, Lewis Ball Holmes. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021. 397: 1276-92. PMID: 33812487Year
2021
Journal
Lancet
Study
IMPAACT 2010
IMPAACT 2016: Operationalizing HIV Intervention Adaptations to Inform the Science and Outcomes of Implementation
Citation
Geri R Doneberg, Dorothy E. Dow, Suad Kapetanovic, Janice Buckley, Tebogo Jacqueline Kakhu, Portia Kamthunzi, Limbika A. Maliwichi, Tichaona Vhembo, Tariro Dianah Chawana, Teacler Nematadzira, Jennifer Libous, Nicole A. MontaƱez. IMPAACT 2016: Operationalizing HIV Intervention Adaptations to Inform the Science and Outcomes of Implementation. Frontiers in Reproductive Health. 2021. 3: 1-9. PMID: 36303985Year
2021
Journal
Frontiers in Reproductive Health
Study
IMPAACT 2016